Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05376891 · ClinicalTrials.gov registry record
Met Non Small Cell Cancer Registry (MOMENT)
A clinical trial of Cancer, sponsored by EMD Serono Research & Development Institute.
- Recruiting
- Registry status
- 700
- Enrollment target
- 20
- Study locations
NCT05376891 is a study of Cancer that is actively recruiting participants, run by EMD Serono Research & Development Institute. The registered enrollment target is 700 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT05376891, a study of Cancer, is actively recruiting participants, sponsored by EMD Serono Research & Development Institute.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy.
Conditions Studied
Study Locations (20)
Other
- Klinikum Klagenfurt Am Woerthersee - Klagenfurt
- Klinik Floridsdorf - Vienna
- AZ Delta - Roeselare
- AZ Nikolaas - Sint-Niklaas
- Ottawa Hospital General Campus - Ottawa
- Princess Margaret Cancer Centre - Toronto
- FN Olomouc - Olomouc
- University Hospital Na Bulovce - Prague
- Centre Hospitalier de Cholet - Cholet
- CHRU Lille - Lille
- Hôpital du Scorff - Lorient
- Centre Leon Berard - Lyon
- Hospital Tenon & University Paris 6 - Paris
- Institut Curie - Centre de Lutte Contre le Cancer (CLCC) - Paris
- CHU de Toulouse Hopital Larrey - Toulouse
- Klinikum Chemnitz GmbH - Chemnitz
- KKH Grosshansdorf GmbH - Großhansdorf
Florida
- Holy Cross Health - Fort Lauderdale
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2022-10-04 |
| Est. Completion | 2028-04-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05376891
The ClinicalTrials.gov registry entry for NCT05376891 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (80% lower). The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05376891 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT05376891 about?
NCT05376891 is a clinical study titled "Met Non Small Cell Cancer Registry (MOMENT)". The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data ...
What is the current status of trial NCT05376891?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2022-10-04. Estimated completion is 2028-04-28.
What conditions does trial NCT05376891 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT05376891?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05376891 being conducted?
This trial has 20 study locations across Florida, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.